Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study – CANCER IMMUNOLOGY IMMUNOTHERAPY

Javier, GC; Alberto, I; Azucena, GNE; Ivan, V; Debora, M; David, P; Laura, A; Andrea, MS; Esther, S; Oleguer, C; Paula, B; Laura, M; Nuria, V; Miquel, N; Patricia, G; Barbara, A; Neus, B; Tamara, S; Manel, J; Aleix, P; Francesco, S – 2023 –...

Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study – CLINICAL CANCER RESEARCH

Vidal, J; Fernandez-Rodriguez, MC; Casadevall, D; Garcia-Alfonso, P; Paez, D; Guix, M; Alonso, V; Cano, MT; Santos, C; Duran, G; Elez, E; Manzano, JL; Garcia-Carbonero, R; Ferreiro, R; Losa, F; Pineda, E; Sastre, J; Rivera, F; Bellosillo, B; Tabernero, J; Aranda, E;...

Unexpected Durable Complete Response With Anti-PD-L1 Blockade in Metastatic Undifferentiated Pleomorphic Sarcoma: A Case Report With Host and Tumor Biomarker Analysis. – JCO precision oncology

Pesantez, David; Indacochea, Alberto; Angelats, Laura; Sirico, Marianna; Victoria, Ivan; Sanfeliu, Esther; Teixido, Cristina; Gonzalez-Navarro, Azucena E; Galvan, Patricia; Braso-Maristany, Fara; Jares, Pedro; Juan, Manel; Prat, Aleix; Schettini, Francesco;...

Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022 – EUROPEAN UROLOGY

GillTssen, S; Bossi, A; Davis, ID; de Bono, J; Fizazi, K; James, ND; Mottet, N; Shore, N; Small, E; Smith, M; Sweeney, C; Tombal, B; Antonarakis, ES; Aparicio, AM; Armstrong, AJ; Attard, G; Beer, TM; Beltran, H; Bjartell, A; Blanchard, P; Briganti, A; Bristow, RG;...